Nachrichten zur Moderna Inc. Aktie

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.…

Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Streets Average Price Target Says It Should Fall 44%. What Gives?

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.…

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.…

MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and…

Jim Cramer turns bullish on health care stock after years of doubt

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism…

Moderna, Eli Lilly & Co. auf Rekordkurs: Warum Anleger zunehmend auf Healthcare-Aktien setzen

Eli Lilly, AbbVie und Moderna erreichen vor dem Wochenende neue Höchststände Moderna stärkster Tagesgewinn im S&P 500: Moderne mRNA-Strategie…

Stocks making the biggest moves midday: Moderna, ON Semiconductor, Rocket Lab, Eli Lilly, Sandisk & more

Here are the companies making headlines in midday trading.…

Moderna, Inc. (MRNA) Discusses Advancements in mRNA Technology, Clinical Modalities, and Future Horizons in Science Transcript

…

The Close 6/25/2026

Bloomberg Television brings you the latest news and analysis leading up to the final minutes and seconds before and after…

Moderna (MRNA) Rises As Market Takes a Dip: Key Facts

Moderna (MRNA) closed at $61 in the latest trading session, marking a +2.79% move from the prior day.…

Should You Buy Moderna Before Aug. 5?

Moderna just received fantastic news.…

Moderna Aktie: FDA-Berater stimmen einstimmig für mRNA-Grippeimpfstoff

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co:Die Analysten von Jefferies bestätigen nach den positiven Empfehlungen des Beratungsgremiums der…

Moderna just got a signal investors can’t ignore

Moderna (MRNA) has been struggling to shake one label for years: Covid winner. That label helped to make the company…

Moderna stock rises on FDA flu vaccine advisory panel review

Moderna stock rises on FDA flu vaccine advisory panel review…

Moderna Aktie +6,6%: Kommt jetzt der Durchbruch beim Grippeimpfstoff?

Bad Marienberg (www.aktiencheck.de) - Moderna-Aktienanalyse: FDA-Termin sorgt für Kurssprung – Kommt jetzt die nächste Wachstumsstory? ????Die Moderna-Aktie sorgt erneut für…

SpaceX and Moderna among market cap stock movers on Tuesday

SpaceX and Moderna among market cap stock movers on Tuesday…

US FDA staff says data may support effectiveness of Modernas flu vaccine in older adults

The U.S. Food and Drug Administrations ?staff reviewers said preliminary assessment of Modernas flu shot data ?may support effectiveness in…

RNAZ: Introducing RNA Therapeutics

By John Vandermosten, CFANASDAQ: RNAZREAD THE FULL RNAZ RESEARCH NOTERNA OncologyRibonucleic acid (RNA) oncology is a specialized field in the…

Moderna gets good news as it searches for life after Covid

Moderna (MRNA) was one of the big beneficiaries of the Covid pandemic, producing tens of billions of dollars in vaccine…

XOMA (XOMA) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DATEWednesday, March 18, 2026 at 8:00 a.m. ETCALL PARTICIPANTSChief Executive Officer — Owen HughesChief Investment Officer…

Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data Transcript

…

Moderna, Inc. (MRNA) Discusses Intismeran mRNA Immunotherapy and Phase II KEYNOTE-942 Oncology Data - Slideshow

…

Moderna CEO Stephane Bancel on INT trial results: Theres duration of efficacy which is exciting

Stephane Bancel, Moderna CEO, joins The Exchange to discuss the companys INT results, how big a drug it could become…

Moderna forciert Pipeline: Erweiterte Partnerschaft mit der CEPI bietet strategische Chancen für Investoren

Moderna erhält bis zu 50 Mio. USD von der CEPI zur Impfstoffentwicklung gegen das Bundibugyo-Ebolavirus. Die etablierte mRNA-Plattform ermöglicht…

Moderna partners with global health coalition to develop Bundibugyo Ebola vaccine

Moderna said on Monday it has partnered with the Coalition for Epidemic Preparedness Innovations ?to develop a potential vaccine against…

Moderna, Inc. (MRNA) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

…

Stocks making the biggest moves premarket: Moderna, Lumentum, Intel, monday.com & more

These are the stocks posting the largest moves premarket.…

Moderna shares extend gains as hantavirus vaccine work draws attention

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) shares continued to extend recent gains on Monday as investors welcomed reports that the company is…

These Stocks Are Today’s Movers: Moderna, Micron, Intel, Apollo Global, and More

Moderna jumps after the U.S. health department says a passenger on a repatriation flight tested mildly positive for hantavirus. Moderna…

Moderna shares jump 8% after U.S. national tests positive for hantavirus

Moderna shares jump 8% after U.S. national tests positive for hantavirus…

Moderna im Hantavirus-Fieber! Zwischen spekulativem Kurssprung und harten Quartalsrealitäten!

Ein lokaler Ausbruch des Hantavirus auf einem Kreuzfahrtschiff treibt die Moderna-Aktie (MRNA) an. Doch abseits der medialen Aufmerksamkeit offenbaren die…

Moderna stock surges on hantavirus vaccine development plans

Moderna stock surges on hantavirus vaccine development plans…

Moderna stock surges on hantavirus vaccine research confirmation

Moderna stock surges on hantavirus vaccine research confirmation…

Moderna: Hantavirus-Schlagzeilen treiben Impfstoff-Aktie an

Das Hantavirus ist auf einem kleinen Kreuzfahrtschiff im Atlantik ausgebrochen. Die Weltgesundheitsorganisation (WHO) hat inzwischen fünf von acht Verdachtsfällen als…

Novavax (NVAX) Q3 2025 Earnings Transcript

Image source: The Motley Fool.DateThursday, Nov. 6, 2025, at 8:30 a.m. ETCall participantsPresident and Chief Executive Officer — John JacobsHead…

Moderna, Inc. (MRNA) Q1 2026 Earnings Call Transcript

…

Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales

MRNA narrows Q1 loss and beats revenue estimates as international vaccine sales surge, lifting shares despite hefty litigation charges.…

Moderna CEO on Earnings, Flu Shots and Skin Cancer Trials

Moderna’s first-quarter sales beat expectations, as the struggling vaccine maker that’s faced resistance from the Trump administration has found new…

Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported first quarter 2026 revenue that came in well above Wall Street expectations, but posted a…

Moderna beats revenue expectations despite wider loss

Moderna beats revenue expectations despite wider loss…

Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales

Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, ?helped by better-than-expected sales of its COVID-19 vaccine in international…

CureVac sues Moderna for patent infringement over COVID-19 vaccines

CureVac sues Moderna for patent infringement over COVID-19 vaccines…

CureVac sues Moderna over mRNA vaccine patents

CureVac sues Moderna over mRNA vaccine patents…

Moderna (MRNA) May Report Negative Earnings: Know the Trend Ahead of Next Weeks Release

Moderna (MRNA) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Moderna (MRNA) Surpasses Market Returns: Some Facts Worth Knowing

In the most recent trading session, Moderna (MRNA) closed at $55.6, indicating a +2.53% shift from the previous trading day.…

Moderna starts late-stage trial of bird flu vaccine in US, UK

Moderna starts late-stage trial of bird flu vaccine in US, UK…

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

Moderna (MRNA) closed the most recent trading day at $54.26, moving +2.69% from the previous trading session.…

Moderna (MRNA) Stock Declines While Market Improves: Some Information for Investors

In the latest trading session, Moderna (MRNA) closed at $51.3, marking a -1.54% move from the previous day.…

Moderna eyes international markets as growth driver, says Bank of America

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026…

Bank of America flags international opportunities as key growth driver for Moderna

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) is expected to highlight progress in international COVID-19 vaccine markets when it reports first quarter 2026…